Aratana Therapeutics price target raised to $38 from $16 at JMP Securities

JMP Securities increased its target on Aratana as the firm thinks the company's acquisition of Vet Therapeutics at least doubles the number of Aratana's compounds that may be approved by 2016 and makes the company the leader in small molecule and monoclonal antibody development for the companion animal market. It keeps an Outperform rating o nthe shares.

View Comments (0)